Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Humanetics, Mount Sinai Sign Agreement - Nutraceuticals World

What are you searching for?

Sign in
Market Updates

Humanetics, Mount Sinai Sign Agreement

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Humanetics, Mount Sinai Sign Agreement
Humanetics Corp., Minneapolis, MN, has signed an exclusive license agreement with Mount Sinai School of Medicine, Manhattan, NY, to further develop and commercialize an oral agent, referenced as NIC5-15, to combat Alz­heimer’s disease. This compound has been shown in pre-clinical studies and animal models to be effective in preventing the formulation of beta amyloid plaques, which are believed to be a cause of Alzheimer’s disease. Humanetics has also entered into a clinical research agreement with investigators at Mount Sinai to test the effect of the compound in humans.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters